Table 2.

FDR-corrected P-values of 14 pathways that are significantly impacted in three Alzheimer’s datasets (GSE5281, GSE84422, and GSE48350). Each dataset is analyzed by three methods (ORA, KS-test, and FGSEA), resulted in 9 analyses (columns 3–11). The last three columns show the meta-analysis results using the addCLT method. The results indicate that these pathways are consistently identified as significant across all analyses

		GSE5281			GSE84422			GSE48350			Meta-analysis
#	Pathway name	ORA	KS	FGSEA	ORA	KS	FGSEA	ORA	KS	FGSEA	ORA	KS	FGSEA
1	Alzheimer disease	4e-09	1e-06	2e-02	4e-05	5e-11	1e-02	1e-02	4e-04	1e-02	4e-07	9e-13	2e-06
2	Huntington disease	4e-12	9e-10	2e-02	2e-05	4e-12	1e-02	8e-04	2e-05	1e-02	6e-11	3e-17	2e-06
3	Parkinson disease	0	4e-13	2e-02	4e-07	0	1e-02	2e-03	1e-04	1e-02	6e-10	2e-14	2e-06
4	Prion disease	9e-11	1e-07	2e-02	8e-05	4e-12	1e-02	1e-03	8e-08	1e-02	2e-10	8e-24	2e-06
5	Pathways of neurodegeneration	1e-11	2e-08	2e-02	4e-06	4e-10	1e-02	2e-03	7e-06	1e-02	3e-10	1e-18	2e-06
6	Oxidative phosphorylation	3e-11	3e-07	2e-02	4e-05	8e-11	1e-02	2e-02	5e-03	1e-02	1e-06	1e-08	2e-06
7	Cardiac muscle contraction	2e-02	1e-02	2e-02	6e-01	3e-01	1e-02	4e-02	9e-02	1e-02	3e-02	1e-02	2e-06
8	Thermogenesis	4e-05	1e-02	2e-02	3e-01	5e-02	1e-02	3e-01	9e-03	1e-02	4e-02	6e-06	2e-06
9	Retrograde endocannabinoid s.	8e-06	1e-03	2e-02	4e-01	7e-04	1e-02	3e-04	3e-07	1e-02	4e-03	3e-11	2e-06
10	Amyotrophic lateral sclerosis	2e-09	2e-06	2e-02	2e-07	1e-10	1e-02	1e-01	2e-03	1e-02	3e-03	6e-10	2e-06
11	GABAergic synapse	8e-02	4e-02	3e-02	9e-02	4e-02	1e-02	4e-03	3e-03	1e-02	7e-05	7e-06	4e-06
12	Spinocerebellar ataxia	4e-03	1e-02	2e-02	3e-03	1e-05	1e-02	8e-02	3e-03	1e-02	3e-04	5e-08	2e-06
13	Non-alcoholic fatty liver d.	7e-06	6e-03	2e-02	3e-01	1e-04	1e-02	2e-01	1e-02	5e-02	2e-02	3e-07	8e-05
14	Morphine addiction	4e-01	7e-01	3e-02	1E+00	6e-01	4e-02	5e-03	9e-04	1e-02	3e-01	8e-01	3e-05